Drug intelligence / Profile preview

AL-801

Development stage: Preclinical
Lead developer: ALPS Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AL-801 is a preclinical-stage monoclonal antibody being developed by ALPS Biotech for the treatment of lung cancer. It targets GM2 ganglioside activator protein (GM2AP), an essential cofactor involved in the lysosomal degradation of ganglioside GM2. By targeting GM2AP, AL-801 aims to inhibit tumor cell survival and progression. ALPS Biotech is also developing a companion diagnostic, AL-801DX, which utilizes GM2AP as a biomarker for early-stage lung cancer screening.

Targets

GM2A (Ganglioside GM2 activator)

Beyond the preview

Go deeper on AL-801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL-801.